AstraZeneca Annual Report and Form 20-F Information 2016
2017 should be a turning point in our journey as we bring new medicines to patients across the globe.
Pascal Soriot, Chief Executive Officer
Financial highlights
Total Revenue*
down 7% to $23,002 million at actual rate of exchange (down 5% at CER)
* As detailed on page 142 of the downloadable PDF of the Annual Report, Total Revenue consists of Product Sales and Externalisation Revenue.
Net cash flow from operating activities
up 25% at actual rate of exchange to $4,145 million
2016 at a glance
A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.
Our strategic priorities reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.
Achieve scientific leadership
Return to growth
Be a great place to work
A science-led, innovation strategy
Distinctive R&D capabilities: small molecule and biologic medicine, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science.
Broad R&D platform in three main therapy areas
Oncology
Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations. We seek to achieve this by means of our combination-focused pipeline that exploits the power of four scientific platforms
Cardiovascular & Metabolic Disease
We push the boundaries of science to create life-changing medicines for patients that reduce morbidity, mortality and organ damage by addressing multiple risk factors
Respiratory
We aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologic medicines along with scientific research targeting disease modification
Portfolio of specialty and primary care products
Oncology
$3,383m
Product Sales (2015: $2,825m, 2014: $3,027m)
Highlights
- Oncology sales represented 16% of Total Product Sales
- Lynparza (sales of $218 million) available in 31 countries by end 2016
- Iressa sales of $513 million, down 6% (5% at CER), as we prioritised Tagrisso
Cardiovascular & Metabolic Disease
$8,116m
Product Sales (2015: $9,489m, 2014: $9,802m)
Highlights
- CVMD sales represented 38% of Total Product Sales
- Sales of Onglyza in the US declined 10% to $376 million, as we prioritised Farxiga
- In the US, Crestor sales declined 57% to $1,223 million, reflecting entry of generic Crestor
Respiratory
$4,753m
Product Sales (2015: $4,987m, 2014: $5,063m)
Highlights
- Respiratory sales represented 22% of Total Product Sales
- Pulmicort sales of $1,061 million, up 5% (8% at CER)
- Bevespi Aerosphere inhalation aerosol launched in the US in January 2017
Other Disease Areas
$5,067m
Product Sales (2015: $6,340m, 2014: $8,203m)
Highlights
- Other sales represented 24% of Total Product Sales
- Nexium sales of $2,032 million, down 19% (18% at CER) and Seroquel XR sales of $735 million, down 28% (27% at CER) following loss of exclusivity
Global commercial presence, with strength in Emerging Markets
US
$7,365m
Product Sales
(2015: $9,474m, 2014: $10,120m)
Europe
$5,064m
Product Sales
(2015: $5,323m, 2014: $6,638m)
Established Rest of World
$3,096m
Product Sales
(2015: $3,022m, 2014: $3,510m)
Emerging Markets
$5,794m
Product Sales
(2015: $5,822m, 2014: $5,827m)
Commercial Highlights:
Growth Platforms grew by 4% (5% at CER) in 2016
- Emerging Markets: Stable (growth of 6% at CER), supported by China, up 4% (10% at CER) to $2,636 million
- Diabetes: Growth of 9% (11% at CER), as Farxiga/Forxiga became our largest-selling Diabetes medicine
- Japan: Sales up 8% (decline of 3% at CER), reflecting exchange rate impact and a biennial price reduction
- Brilinta/Brilique sales grew by 36% (39% at CER)
- Respiratory: A decline of 5% (3% at CER), reflecting US pricing pressure for Symbicort
- New Oncology: Strong sales with Tagrisso delivering sales of $423 million in its first full year
Our talented employees are committed to achieving our Purpose in a sustainable way and our Values foster a strong AstraZeneca culture
Research Centres
1) California, US 2) Gaithersburg, MD, US 3) Boston, MA, US 4) Gothenburg, Sweden
5) Shanghai, China 6) Osaka, Japan
59,700 Employees
92%
Cambridge, UK (HQ)
Gothenburg, Sweden
Gaithersburg, Maryland US
Dividends
Our capital-allocation priorities strike a balance between the interests of the business, our financial creditors and shareholders, and support our progressive dividend policy.
| Distributions to shareholders $m | 2016 | 2015 | 2014 |
|---|---|---|---|
| Dividends |
3,561 |
3,486 |
3,521 |
| Proceeds from issue of shares |
(47) | (43) | (279) |
| Total | 3,514 | 3,443 | 3,242 |
| Dividend per Ordinary Share $ | 2016 | 2015 | 2014 |
|---|---|---|---|
| Dividend per Ordinary Share |
2.80 | 2.80 | 2.80 |
| Dividend per Ordinary Share for 2016 | $ |
Pence |
SEK |
Payment Date |
|---|---|---|---|---|
| First interim dividend | 0.90 |
68.7 |
7.81 |
12 September 2016 |
| Second interim dividend | 1.90 |
150.2 |
16.57 |
20 March 2017 |
| Total | 2.80 |
218.9 |
24.38 |
AstraZeneca’s Directors take very seriously their responsibility to have a robust governance structure in place.
Leif Johansson, Chairman
